查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405863

流感治疗市场规模、份额、趋势分析报告：依治疗药物、给药途径、配销通路、地区、细分市场预测，2024-2030年

Influenza Treatment Market Size, Share & Trends Analysis Report By Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

流感治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球流感治疗市场预计将达到64.4亿美元，2024年至2030年复合年增长率为1.18%。

该市场的成长是由于流感盛行率的上升以及对治疗该疾病的有效疗法的需求不断增长。此外，主要企业不断致力于开发新的治疗方法，以满足对精准药物治疗不断增长的需求，FDA 正在倡议核准流感治疗药物。因此，全球对治疗的持续需求正在推动整体市场的成长。

此外，季节性流感和呼吸道疾病盛行率的上升也推动了对新疗法的需求。据美国疾病管制与预防中心(CDC)称，2010年至2020年间，美国流感造成的负担估计为每年900万至4100万人患病、14万至71万人住院、12000至52000人死亡。预计这将导致。同样，初步调查结果表明，从 2021 年到 2022 年，将有约 900 万人报告出现症状，约 400 万人次就诊，10 万人住院治疗，5,000 人死亡。

市场成长是由病毒感染疾病创新疗法的持续核准和即将商业化所推动的。例如，2022年8月，罗氏宣布美国FDA核准Xofluza（baloxavir marboxil）用于治疗5至12岁有症状48小时儿童的急性流感。此外，该行业的领导者在过去2至3年内推出了多种治疗病毒感染疾病的新药，导致市场上其他小型企业占据了很大的收益占有率，这支持了对新药开拓的需求。

此外，COVID-19大流行显着促进了市场成长。在大流行期间，有效控制疾病的需要导致对抗新型冠状病毒的广谱抗病毒药物的需求激增。瑞德西韦、法匹拉韦、奥司他韦和各种联合治疗药物已被广泛用于治疗 COVID-19。此外，政府正在向製药公司分配更多资金，以加速针对 COVID-19 的新疗法的开发。例如，2021年6月，美国政府宣布投资超过30亿美元，加速抗病毒药物的发现、製造和开发。随着发病率持续上升以及研发工作的加强，预计未来两到三年抗病毒药物的需求将会增加。

此外，主要参与企业正在采取各种策略，例如产品发布、联盟/合作和併购，以扩大其国际足迹并保持在流感治疗市场的竞争地位。例如，2020年11月，盐野义的XOFLUZA（Baloxavir Marboxil）获得FDA核准作为流感预防药物。同样，2021年2月，FDA扩大了对BioCryst Pharmaceuticals的产品帕拉米韦注射液Rapivab的核准。本产品广泛用于治疗 6 个月以上、出现症状两天的患者的急性、无併发症的流感。

流感治疗药物市场报告亮点

  • 以治疗药物来看，2023年磷酸奥司他韦製剂占市场最大销售份额。
  • 从给药途径来看，由于给药方便，口服药物的采用正在增加，就2023年的销售份额而言，口服药物在市场上占据主导地位。
  • 按配销通路，由于住院患者数量增加以及医院药房配药的利用率增加，医院药房细分市场将在 2023 年占据主导地位。
  • 由于老字型大小企业的存在、季节性流感疫情的增加以及流感导致的住院人数的增加，北美在 2023 年占据了最大的份额。

目录

第一章流感治疗市场：调查方法与范围

第二章流感治疗市场：执行摘要

  • 市场概述
  • 治疗概况及给药途径
  • 配销通路简介
  • 竞争形势概览

第三章流感治疗市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • 更多 FDA核准的新流感药物
    • 流感等传染性呼吸道疾病的传播；
  • 市场抑制因素分析
    • 与流感治疗相关的复杂症状
  • 波特五力分析
  • PESTLE分析

第四章流感治疗市场：治疗估计与趋势分析

  • 流感治疗市场：治疗变异分析
  • 帕拉米韦
    • 2018-2030 年帕拉米韦市场估计与预测
  • 扎那米韦
    • 扎那米韦市场估计与预测，2018-2030
  • 巴洛沙韦酯
    • Baloxavir marboxil 市场估计与预测，2018-2030
  • 磷酸奥司他韦
    • 2018-2030年磷酸奥司他韦市场估计与预测
  • 其他的
    • 2018-2030 年其他市场估计与预测

第五章流感治疗市场：给药途径预估及趋势分析

  • 流感药物市场：给药变化分析
  • 口服
    • 2018-2030 年口腔市场估计与预测
  • 其他的
    • 2018-2030 年其他市场估计与预测

第六章 流感治疗药物市场：配销通路估算及趋势分析

  • 流感治疗药物市场：配销通路波动分析
  • 医院药房
    • 2018-2030 年医院药局市场估计与预测
  • 零售药房
    • 2018-2030 年零售药局市场估计与预测
  • 网路药房
    • 2018-2030 年线上药局市场估计与预测

第七章流感治疗市场：区域业务分析

  • 区域市场简介
  • 北美洲
    • 2018-2030 年北美流感治疗市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲流感治疗市场，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 亚太地区流感治疗市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲流感治疗市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 中东和非洲流感治疗市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 公司分类
  • 策略规划
    • 新推出
    • 合伙
    • 获得
    • 合作
  • 2023年主要企业市场占有率分析
  • 企业热力图分析
  • 公司简介
    • Natco Pharma Limited
    • Novartis Ag
    • F. Hoffmann-la Roche Ltd
    • Biocryst Pharmaceuticals, Inc.
    • Sanofi
    • Gsk Plc.
    • Viatris Inc.（Mylan）
    • Teva Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited.
    • Astrazeneca
Product Code: GVR-4-68040-168-6

Influenza Treatment Market Growth & Trends:

The global influenza treatment market is expected to reach USD 6.44 billion by 2030, expanding at a CAGR of 1.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of influenza aided by the rising need for efficient therapeutics to treat the condition. Furthermore, key players are constantly focusing on developing novel therapeutics to meet the rising demand for precise medication with constant initiative by the FDA for approval of influenza treatment drugs. As a result of which, the constant demand for treatment globally is fueling the growth of the overall market.

Additionally, the rising prevalence of seasonal flu and respiratory diseases has boosted the demand for novel therapeutics. According to CDC, it is estimated that the burden of flu in the U.S. had resulted in 9 million -41 million illnesses, 140,000 - 710,000 hospitalizations, and 12,000 - 52,000 deaths yearly between 2010 and 2020. Similarly, according to preliminary results around 9 million individuals had symptomatic illnesses, and approximately 4 million medical visits, 100,000 hospitalizations, and 5 thousand deaths were reported from 2021 to 2022.

The market growth is expected to be driven by the increasing approval and upcoming commercialization of innovative medications for viral infections. For instance, in August 2022, Roche announced the U.S. FDA approval for Xofluza (baloxavir marboxil), used for the treatment of acute influenza in children aged 5 to 12 years who have been symptomatic for 48 hours. Additionally, prominent players in the industry have introduced several novel medicines for viral infections within the span of 2 to 3 years propelling the need for the development of novel medication by other small players operating in the market in order to generate significant revenue share.

Moreover, the COVID-19 pandemic has significantly boosted the growth of the market. During the pandemic, the demand for broad-spectrum antiviral drugs to combat the novel coronavirus has surged due to the need to manage the disease effectively. Medications like Remdesivir, favipiravir, oseltamivir, and various combination therapies have become widely prescribed for treating COVID-19. Additionally, governments are allocating greater funding to pharmaceutical companies to expedite the development of novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government announced an investment of over USD 3 billion to accelerate the discovery, manufacturing, and development of antiviral medicines. As the incidence of the disease continues to rise and research and development efforts intensify, the demand for antiviral drugs is expected to increase in the next 2 to 3 years.

Furthermore, the key participants are engaged in various strategies such as product launches, partnerships & collaborations, and mergers & acquisitions, to expand their global footprints and maintain their competitive position in the influenza treatment market. For instance, in November 2020, Shionogi's XOFLUZA (Baloxavir Marboxil) received FDA approval for the prevention of influenza. Similarly, in February 2021, FDA expanded the approval of Rapivab which is a peramivir injection, a product of BioCryst Pharmaceuticals. The product is extensively used for treating acute uncomplicated influenza in 6 months of age & older patients who have been symptomatic for 2 days.

Influenza Treatment Market Report Highlights:

  • Based on treatment, the oseltamivir phosphate segment held the largest revenue share in 2023 in the market owing to the rising prevalence of influenza leading to increasing prescription of oseltamivir phosphate
  • Based on route of administration, the oral segment dominated the market with a revenue share in 2023 attributed to the increased adoption of oral drug products due to their ease of administration
  • On the basis of distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the rising hospitalization and use of hospital pharmacies for medication
  • North America held the largest share in 2023 owing to the presence of well-established players, the rising prevalence of seasonal flu, and an increased hospitalization due to the condition

Table of Contents

Chapter 1. Influenza Treatment Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Influenza Treatment Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Treatment and Route of Administration Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Influenza Treatment Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising new FDA-approved influenza treatment drugs
    • 3.4.2. Prevalence of contagious respiratory illness such as influenza
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complicated conditions associated with influenza treatment
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Influenza Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Influenza Treatment Market: Treatment Movement Analysis
  • 4.2. Peramivir
    • 4.2.1. Peramivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Zanamivir
    • 4.3.1. Zanamivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Baloxavir Marboxil
    • 4.4.1. Baloxavir Marboxil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oseltamivir Phosphate
    • 4.5.1. Oseltamivir Phosphate Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Influenza Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Influenza Treatment Market: Route of Administration Movement Analysis
  • 5.2. Oral
    • 5.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Others
    • 5.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Influenza Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Influenza Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacies
    • 6.4.1. Online Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Influenza Treatment Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Influenza Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. France
      • 7.3.4.1. France Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. Italy
      • 7.3.5.1. Italy Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Spain
      • 7.3.6.1. Spain Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Norway
      • 7.3.8.1. Norway Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-pacific Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Australia
      • 7.4.6.1. Australia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
  • 8.3. Key Company Market Share Analysis, 2023
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Natco Pharma Limited
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Novartis Ag
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-la Roche Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Biocryst Pharmaceuticals, Inc.
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Sanofi
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Gsk Plc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Viatris Inc. (Mylan)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Daiichi Sankyo Company, Limited.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Astrazeneca
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Influenza Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 North America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 5 North America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 North America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 Europe Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Germany Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Germany Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 22 UK Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 UK Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 France Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 France Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 France Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Spain Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 28 Spain Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Spain Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 Italy Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Denmark Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 34 Denmark Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Denmark Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Norway Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 37 Norway Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Norway Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Sweden Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Sweden Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Japan Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 47 Japan Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Japan Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 China Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 China Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 India Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 India Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 India Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Australia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 56 Australia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Australia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Korea Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 South Korea Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Thailand Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 65 Latin America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Latin America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 69 Brazil Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 Mexico Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 72 Mexico Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Mexico Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Argentina Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 75 Argentina Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Argentina Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 UAE Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 88 UAE Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 UAE Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global influenza treatment market- Key market driver analysis
  • Fig. 7 Global influenza treatment market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global influenza treatment market - Porter's analysis
  • Fig. 10 Global influenza treatment market - PESTEL analysis
  • Fig. 11 Global influenza treatment market: Treatment outlook key takeaways
  • Fig. 12 Global influenza treatment market: Treatment movement analysis
  • Fig. 13 Peramivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Zanamivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Baloxavir marboxil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Oseltamivir phosphate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Global influenza treatment market: Route of Administration outlook key takeaways
  • Fig. 19 Global influenza treatment market: Route of Administration movement analysis
  • Fig. 20 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Global influenza treatment market: Distribution Channel outlook key takeaways
  • Fig. 23 Global influenza treatment market: Distribution Channel movement analysis
  • Fig. 24 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Global influenza treatment market: Regional movement analysis
  • Fig. 29 North America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 UK influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 France influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 China influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 India influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Strategy framework